PnuVax

What PnuVax does

PnuVax, Inc. is a privately held biopharmaceutical company founded in 2008 and headquartered in Kingston, Canada, with manufacturing operations in Montreal and a US office in Burlington, Vermont. The company focuses on biomanufacturing and vaccine production, applying process intensification and modern materials to lower bioprocessing costs. Its cGMP-capable manufacturing infrastructure includes pilot-scale studies up to 70L, scale-up studies up to 200L, large-scale bacterial cultures up to 3,500L (with BSL-2 capability at commercial scale), large-scale mammalian and viral cultures up to 2,500L, and hand fills up to 2,000 vials for clinical and investigational materials.

The company operates a dual product and service offering. On the services side, it delivers bespoke contract development and manufacturing for biopharmaceutical and cellular agriculture customers across laboratory, pilot, and commercial scales, with capability for new modalities and animal-free ingredient adaptation. On the products side, it sells standardized cGMP lyophilized pneumococcal polysaccharides through an online storefront in 1mg, 10mg, and 20mg units priced at $495, $4,895, and $8,995 respectively, with a broad catalog of serotypes. Warehousing services with CRT, refrigerated, and cryogenic storage plus 3PL capabilities round out the offering.

PnuVax serves biopharmaceutical companies requiring cGMP contract manufacturing, cellular agriculture companies developing food products through bioprocessing, and smaller-scale customers and researchers purchasing standardized polysaccharides online. The go-to-market combines enterprise direct sales for custom manufacturing with self-serve e-commerce for catalog products. Co-founder and President Don Gerson previously co-founded Celltrion and Innovent and oversaw 3 billion-plus doses of production at Wyeth and Connaught; co-founder Jonas Gerson is a bioprocess engineering specialist in cGMP facility design; Allison Turner leads process intensification and compliance. The company received a $29.4M grant from the Bill & Melinda Gates Foundation in October 2017 and states it is actively accepting new clients with available capacity.

Name

PnuVax

Legal name

PnuVax, Inc.

Website

https://pnuvax.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

PnuVax, Inc. is a private biopharmaceutical contract manufacturer founded in 2008 in Kingston, Canada, offering cGMP biomanufacturing services for biopharmaceuticals and cellular agriculture, plus standardized cGMP pneumococcal polysaccharides sold online.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)

Keywords

• CGMP biomanufacturing services
• Vaccine contract manufacturing
• Pneumococcal polysaccharide production
• Biopharmaceutical CDMO services
• Cellular agriculture manufacturing

Headquarters

HQ city

Kingston

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Bespoke contract development and manufacturing services for biopharmaceuticals and cellular agriculture products, from pilot scale through commercial production. Services include upstream/downstream processing, warehousing, and clinical material production.
2. cGMP Product Sales: Direct sales of cGMP lyophilized pneumococcal polysaccharides through e-commerce storefront, available in multiple serotypes and quantity tiers.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels1 record

Core offering

PnuVax is a biomanufacturing company that provides cGMP contract development and manufacturing services for biopharmaceuticals and cellular agriculture products, spanning pilot to commercial scale (bacterial cultures up to 3500L, mammalian/viral cultures up to 2500L), with sterile fill-finish, lyophilization, and temperature-controlled warehousing. It also directly sells standardized cGMP lyophilized pneumococcal polysaccharides in 1mg, 10mg, and 20mg unit sizes across more than 20 serotypes through an online store.

Product overview

PnuVax is a biomanufacturing company offering a dual portfolio of products and services. The products include cGMP Lyophilized Pneumococcal Polysaccharide in three sizes (1mg at $495, 10mg at $4,895, and 20mg at $8,995), sold directly through their online store with selectable serotypes. The services include BioPharma Manufacturing (laboratory to commercial scale with full GMP capabilities), Warehousing (CRT, refrigerated, and cryogenic storage; 3PL capable), and Cellular Agriculture Services (supporting fungi to cells). The company operates cGMP-capable manufacturing suites with pilot-scale studies up to 70L, scale-up studies up to 200L, large-scale bacterial cultures up to 3500L, large-scale mammalian/viral cultures up to 2500L, and hand fills up to 2000 vials, including BSL-2 capability at commercial scale.

Differentiator

Problem solved

Functional benefit

Products and services

• cGMP Lyophilized Pneumococcal Polysaccharide - 1mg Compendial lyophilized pneumococcal polysaccharide supplied as 1mg of lyophilized powder, available in multiple serotypes, sold directly through the PnuVax online store for use by vaccine developers and researchers.
• cGMP Lyophilized Pneumococcal Polysaccharide - 10mg Compendial lyophilized pneumococcal polysaccharide supplied as 10mg of lyophilized powder, available in multiple serotypes, sold directly through the PnuVax online store for use by vaccine developers and researchers.
• cGMP Lyophilized Pneumococcal Polysaccharide - 20mg Compendial lyophilized pneumococcal polysaccharide supplied as 20mg of lyophilized powder, with selectable serotype and additional serotypes available on request, sold directly through the PnuVax online store for use by vaccine developers and researchers.
• Biopharma Contract Manufacturing Services Contract development and manufacturing services for biopharmaceutical products, available at laboratory, pilot, and commercial scales with R&D to full cGMP capabilities across a range of modalities. Targeted at biopharma companies needing process intensification, scale-up, and commercial cGMP production capacity.
• Cellular Agriculture Contract Manufacturing Services Manufacturing services for cellular agriculture products, from laboratory scale to full commercial scale, supporting products derived from fungi to cells for cellular agriculture companies developing novel food products.
• Temperature-Controlled Warehousing Services Storage services for biopharmaceutical and cellular agriculture materials ranging from a single vial to thousands of pallets, with controlled room temperature (CRT), refrigerated, and cryogenic storage options, operated on a 3PL basis.

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• WuXi Biologics: WuXi Biologics is a global CDMO offering end-to-end biologics development and manufacturing services from clinical to commercial scale. It is the dominant scale player in mammalian-cell biologics contract manufacturing, competing for the same biopharma capacity shortfall that PnuVax targets.
• Lonza Group: Lonza is one of the world's largest CDMOs across biologics, cell and gene therapies, and small molecules, with cGMP manufacturing suites globally. Comparable to PnuVax in offering mammalian and microbial biomanufacturing services at commercial scale, though at much larger volumes.
• Catalent: Catalent is a large CDMO with biologics, sterile fill-finish, and vaccine manufacturing capabilities, serving similar biopharma customers. PnuVax's sterile hand-fill and lyophilization services overlap directly with Catalent's softgel/sterile franchises.
• Samsung Biologics: Samsung Biologics is a top-tier biologics CDMO with very large-scale mammalian cell culture capacity. Competes for the same commercial-scale biopharmaceutical manufacturing contracts as PnuVax with substantial scale advantages.
• Charles River Laboratories: Charles River operates CDMO/biologics services (via its CDMO segment acquired through Cognate BioServices) covering cell and gene therapy and vaccine development. Comparable to PnuVax in offering end-to-end biopharmaceutical development and manufacturing services.

Direct peers

• AGC Biologics: AGC Biologics is a mid-size CDMO offering microbial and mammalian biomanufacturing services from clinical to commercial scale across multiple sites. Most directly comparable to PnuVax in facility size, scope of services, and target biopharma customer base.
• Cytovance Biologics: Cytovance is a US-based biologics CDMO offering microbial fermentation, mammalian cell culture, and fill-finish services. Closely matches PnuVax's cGMP microbial/mammalian service portfolio and SMB biopharma customer focus.
• IDT Biologika: IDT Biologika is a CDMO specializing in vaccines and biopharmaceuticals with bacterial and viral manufacturing capabilities. Strongly comparable to PnuVax in vaccine/bacterial-process specialization and process development focus.
• Emergent BioSolutions: Emergent BioSolutions operates contract manufacturing and own vaccine/biologic product businesses, including bacterial polysaccharide and conjugate vaccine capabilities. Comparable to PnuVax in combining CDMO services with proprietary vaccine product sales.
• Bavarian Nordic: Bavarian Nordic is a vaccine manufacturer with cGMP biomanufacturing capabilities, working with public health agencies globally. Comparable to PnuVax's mission-driven vaccine focus and cGMP bacterial/viral manufacturing operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/pnuvax-incorporated

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PnuVax